Background {#Sec1}
==========

The main incident in neurological disorders is excitotoxicity which entails an extensive upsurge in the concentrations of intracellular Ca^2+^ and the production of reactive species such as ROS and RNS by lethal pathways \[[@CR1]\]. In addition, there are alterations of the mitochondrial ultrastructure and DNA damage caused by nitric oxide- (NO-) dependent oxidative stress \[[@CR2]\]. This damage is the primary event in 3-nitropropionic acid (3-NPA) toxicity.

In Wistar rats, it has been reported that 3-nitropropionic acid leads to neurodegeneration and that the intravenous administration in rats provides valuable insight of Huntington's disease model \[[@CR3]\]. There is evidence that metabolism of transmitter dopamine by monoamine oxidase enzyme may promote striatal damage in mitochondrial toxin induced models of Huntington's disease (HD) \[[@CR4]\], and that HD is a devastating neurodegenerative disorder that reflect neuronal dysfunction and ultimately death in selected brain regions with striatum and cerebral cortex being the principal targets \[[@CR5]\]. Some nutrients are known to act as antioxidants; and although neglected as an antioxidant, riboflavin is one of such nutrients that independently or as a component of the glutathione redox cycle has an important antioxidant action \[[@CR6]\]. On the other hand, pyridoxine alters serotonin metabolism \[[@CR7]\]. Both compounds are water-soluble vitamins that possess antioxidant activity \[[@CR8]\].

Neuromodulation activity of the NO- is a documented fact, however, an excess amount of it can produce oxidative damage or nitroso-glutathione (NOGSH) inside the cell, thus; causing the damage of the cell \[[@CR9]\]. It is known that free radicals (FR) induce damage to the components of the cell \[[@CR10]\]. Such FR-induced damage particularly affects the plasma membrane lipids \[[@CR11]\]. In addition, the cells of the central nervous system are extremely susceptible to these unpaired electron molecular species. Nitric oxide (NO) acts on hypothalamic neurocircuits and on higher brain circuits, e.g. dopaminergic system to regulate energy and glucose homeostasis \[[@CR12]\]. Therefore, the presence of FR may upset this regulatory function of NO. The structural proteins in the lipid bilayer are contiguous with brain plasma membrane phospholipids \[[@CR13]\] and the ionic inflow and outflow through the lipid bilayer is maintained by Na^+^, K^+^ ATPase enzyme which stimulates Na^+^ and K^+^ flows \[[@CR14]\]. It is know that when the activity of the enzyme Na^+^, K^+^ ATPase is inhibited, it triggers the release of excitatory amino acid in the CNS \[[@CR15]\].

In view of all the aforementioned, the objective of the present work was to make a comparative analysis of the protective effects derivable from riboflavin (B~2~) and pyridoxine (B~6~) on 5-HIAA and dopamine levels, as well as on selected markers of oxidative stress in rats' brain regions after an induction of Huntington's disease (HD). Literature reports suggest that these substances may participate in the neutralization of excess free radicals in oxidation mechanisms. The production of free radicals, a usual biological phenomenon, is regulated by different metabolic routes, which constitute the first line of defence in the human body.

The aim of this work was to determine if riboflavin (B~2~) and pyridoxine (B~6~) provide protection to the brain against free radicals generated by 3-nitropropionic acid (3-NPA) by measuring the levels of dopamine (DA) and selected oxidative stress markers.

Materials and methods {#Sec2}
=====================

Thirty-six male Wistar rats (250 g) were procured from Bioterium of Metropolitan University of Mexico City and housed in clean plastic cages, separated into 6 groups and treated as follows: group 1, control (NaCl 0.9%); group 2, 3-NPA (20 mg/kg); group 3, B~2~ (10 mg/kg); group 4, B~2~ (10 mg/kg) + 3-NPA (20 mg/kg); group 5, B~6~ (10 mg/kg); group 6, B~6~ (10 mg/kg) + 3-NPA (20 mg/kg), each group N = 6. The administration of treatments was by i.p. The animals received the drugs every 24 h during 3 days. At the end of the treatment period and 30 min after the last drug administration, the animals were sacrificed with guillotine without anaesthetic procedure. The animal brains were immediately extirpated and put in saline solution (NaCl 0.9%) at 4 °C. Tissues were immediately dissected in regions and used to evaluate reduced glutathione (GSH), H~2~O~2~, lipid peroxidation, ATPase, and the levels of DA and 5-hydroxyindolacetic acid (5-HIAA).

The rats or breeds employed in the study were subjected to a selection process based on phenotypic variety; genetic, environmental and compartmental factors. Longitudinal weight curves, weight and physical exploration were the means employed to select a breed for inclusion or exclusion in the study. Also, to select a breed, it is fundamental that inbreeding is non-existence, thus having a hereditary control of traits with continuous variation.

The selected animals were kept in cool and dry place at a temperature of 15--16 °C and with air filter and humidity of between 50 and 60. The place was maintained clean and was continuously sterilized to avoid bacterial and fungal growth.

The breeds were fed with standardized diet based on 3800 kcal/kg, proteins 12%, fat 5%, vitamins and minerals. The selected animals were 3 months old male Wistar of approximately 250 g weight.

Brain extraction {#Sec3}
----------------

On sacrificing the animals, the brains were excised from the base. Then, the brain tissue was dissected in cortex, striatum and cerebellum/medulla oblongata, weighed and homogenised in 5 volumes of 0.05 M tris--HCl, pH 7.4. An aliquot of the homogenized brain tissue was obtained and again homogenised in 0.1 M perchloric acid (HClO~4~) (50:50 v/v) using Yamato homogenizer (Yamato lh-21 LSC Lab, Dallas, USA) and stored at − 20 °C until analysed.

Animal management and care was conducted in accordance to the international guidelines for animal care and to the Mexican Guidelines ZOO-062. Besides, the study was approved by the Laboratory Animals Use and Care Committee of National Institute of Pediatrics.

Measurement of Dopamine (DA) {#Sec4}
----------------------------

The DA levels were measured in the supernatant of tissue homogenized in HClO4 after centrifugation at 5000*g* for 10 min in a microcentrifuge (Hettich Zentrifugen, model Mikro 12-42, Tuttlingen, Germany), with a version of the technique reported by Calderon et al. \[[@CR16]\]. An aliquot of the HClO4 supernatant, and 1.9 mL of buffer (0.003 M octyl-sulphate, 0.035 M KH~2~PO~4~, 0.03 M citric acid, 0.001 M ascorbic acid), were placed in a test tube. The mixture was incubated for 5 min at room temperature in total darkness, and subsequently, the samples were read in a spectrofluorometer (Perkin Elmer LS 55, Buckinghamshire, England) with 282 nm excitation and 315 nm emission lengths. The FL Win Lab version 4.00.02 software was used. Values were inferred in a previously standardized curve and reported as nMoles/g of wet tissue.

Measurement of 5-HIAA {#Sec5}
---------------------

5-HIAA levels were measured in the supernatant of tissue homogenized in HClO~4~ after centrifugation at 5000*g* for 10 min in a microcentrifuge (Hettich Zentrifugen), with a modified version of the technique reported by Beck et al. \[[@CR17]\]. An aliquot of the HClO~4~ supernatant, and 1.9 mL of acetate buffer 0.01 M pH 5.5 were placed in a test tube. The mixture was incubated for 5 min at room temperature in total darkness, and subsequently, the samples were read in a spectrofluorometer (Perkin Elmer LS 55) with 296 nm excitation and 333 nm emission lengths. The FL Win Lab version 4.00.02 software was used. Values were inferred in a previously standardized curve and reported as nMoles/g of wet tissue.

Measurement of reduced glutathione (GSH) {#Sec6}
----------------------------------------

GSH levels were measured from the supernatant of the perchloric acid homogenised tissue, obtained after centrifuging at 5000*g* for 5 min (Hettich Zentrifugen) according to a modified method of Hissin and Hilf \[[@CR18]\]. A 1.8 mL phosphate buffer pH 8.0 with EDTA 0.2% plus a 20 μL aliquot of the supernatant and 100 mL of ortho-phthaldehyde (OPT) 1 mg/mL in methanol were put in a test tube and mixed. The mixture was then incubated for 15 min at room temperature in absolute darkness. At the end of the incubation time, the samples were read in a spectrophotometer (Perkin Elmer LS 55), with excitation and emission wavelengths of 350 and 420, respectively. FL Win Lab version 4.00.02 software was used. Values were inferred from a previously standardised curve and expressed as nM/g.

Measurement of lipid peroxidation {#Sec7}
---------------------------------

The lipid peroxidation across the reactive substances to the thiobarbituric acid (Tbars) determination was carried out using the modified technique of Gutteridge and Halliwell \[[@CR11]\], as described below: From the homogenized brain in tris--HCl 0.05 M pH 7.4, 1 mL was taken and to it was added 2 mL of thiobarbituric acid (Tba) containing 1.25 g of Tba, 40 g of trichloroacetic acid (Tca), and 6.25 mL of concentrated chlorhydric acid (HCl) diluted in 250 mL of deionized H~2~O. The mixture was heated to boiling point for 30 min. (Thermomix 1420) and then cooled in an ice bath for 5 min. after which it was centrifuged at 700*g* for 15 min. (Sorvall RC-5B Dupont). The absorbance of the floating tissues was read in triplicate at 532 nm in a spectrophotometer (Helios de UNICAM). The concentration of TBARS was expressed in µM of Malondialdehyde/g of wet tissue.

Measurement of total ATPase {#Sec8}
---------------------------

The activity of ATPase was assayed according to the method proposed by Calderón et al. \[[@CR19]\]. 1 mg (10%) w/v of homogenised brain and heart tissues in tris--HCl 0.05 M pH 7.4 was incubated for 15 min in a solution containing 3 mM MgCl~2~, 7 mM KCl, and 100 mM NaCl. To this was added 4 mM tris-ATP and incubated for another 30 min at 37 °C in a shaking water bath (Dubnoff Labconco, TX, USA). 100 µL trichloroacetic acid at 10% w/v was used to stop the reaction and the samples were centrifuged at 100*g* for 5 min at 4 °C. Inorganic phosphate (Pi) was measured in triplicates using one supernatant aliquot as proposed by Fiske and Subarrow \[[@CR20]\]. Supernatant absorbance was read at 660 nm in a Helios-α, UNICAM spectrophotometer and expressed as mM Pi/g wet tissue per minute.

Measurement of H~2~O~2~ {#Sec9}
-----------------------

The determination of H~2~O~2~ was made using the modified technique of Asru \[[@CR21]\]. Each brain region (cortex, striatum, cerebellum/medulla oblongata) was homogenized in 3 mL of tris--HCl 0.05 M pH 7.4 buffers. From the diluted homogenates, 100 µL was taken and mixed with 1 mL of potassium dichromate solution (K~2~Cr~2~O~7~). The mixtures were heat to boiling point for 15 min (Thermomix 1420, CA, USA). The samples were later placed in an ice bath for 5 min and centrifuged at 3000*g* for 5 min (Hettich Zentrifugen). The absorbance of the floating was read in triplicate at 570 nm in a spectrophotometer (Heλios-α of UNICAM, Bristol, UK). The concentration of H~2~O~2~ was expressed in µMoles.

Statistical analysis {#Sec10}
--------------------

One way analysis of variance (ANOVA) or Non parametric Kruskal--Wallis test was used after the data have been subjected to variances homogeneity test. Post hoc Tukey--Kramer or Steel--Dwass contrast was employed. The values of *p* \< 0.05 were considered statistically significant \[[@CR22]\]. JMP Statistical Discovery Software version 10.0 from SAS was used.

Results {#Sec11}
=======

In cortex, the administration of 3-NPA produced a significant increase in the levels of dopamine as well as a significant decrease in the levels of 5-HIAA (Fig. [1](#Fig1){ref-type="fig"}). GSH decreased in all animals groups that received the treatments however, the decrease of GSH had statistical significant difference only in those treated with Rivoflavin (B~2~), Rivoflavin (B~2~) + 3-NPA and Pyridoxine (B~6~) + 3-NPA when compared with the control group (Fig. [2](#Fig2){ref-type="fig"}). Significant lipid peroxidation was appreciated in animals treated with Rivoflavin in comparison with control, B~2~ + 3-NPA and B~6~ + 3-NPA groups (Fig. [3](#Fig3){ref-type="fig"}). Calcium Magnesium dependent ATPase activity increased significantly in the group of animals that received 3-NPA when compared with other treatments (Fig. [4](#Fig4){ref-type="fig"}). In this region, the changes in H~2~O~2~ levels did not have statistical differences among treated and control groups (Fig. [5](#Fig5){ref-type="fig"}).Fig. 15-HIAA levels in brain of rats treated with NaCl (G1), 3-Nitropropionic acid 3-NPA (G2), Riboflavin B~2~ (G3), Riboflavin B~2~ + 3-NPA (G4), Pyridoxine B~6~ (G5) and Pyridoxine B~6~ + 3-NPA (G6). Data presented as Mean ± SD values of percentage with respect to NaCl control group. Assays were made by triplicate. Cortex: Anova F = 11.06; *p* \< 0.0001; \**p* \< 0.0004 3-NPA versus control, B~2~, B~2~ + 3-NPA, B~6~, B~6~ + 3-NPA. Striatum: Anova F = 10.3; *p* \< 0.0001; \**p* \< 0.006 3-NPA versus control, B~2~, B~2~ + 3-NPA, B~6~, B~6~ + 3-NPA. Cerebellum/medulla oblongata: Anova F = 4.9; *p* = 0.002; \**p* \< 0.02 3-NPA versus control and B~6~ + 3-NPA Fig. 2GSH levels in brain of rats treated with NaCl (G1), 3-Nitropropionic acid 3-NPA (G2), Riboflavin B~2~ (G3), Riboflavin B~2~ + 3-NPA (G4), Pyridoxine B~6~ (G5) and Pyridoxine B~6~ + 3-NPA (G6). Data presented as Mean ± SD values of percentage with respect to NaCl control group. Assays were made by triplicate. Cortex: Anova F = 3.97; *p* = 0.008; \**p* \< 0.05 control versus 3-NPA, B~2~ + 3-NPA, B~6~ + 3-NPA. Striatum: Anova F = 0.02; *p* = 0.95. Cerebellum/medulla oblongata: Anova F = 1.8; *p* \< 0.13 Fig. 3TBARS levels in brain of rats treated with NaCl (G1), 3-Nitropropionic acid 3-NPA (G2), Riboflavin B~2~ (G3), Riboflavin B~2~ + 3-NPA (G4), Pyridoxine B~6~ (G5) and Pyridoxine B~6~ + 3-NPA (G6). Data presented as Mean ± SD values of percentage with respect to NaCl control group. Assays were made by triplicate. Cortex: Anova F = 4.60; *p* = 0.003; \**p* \< 0.05 B~2~ versus control, B~2~ + 3-NPA, B~6~ + 3-NPA. Striatum: Anova F = 21.5; *p* \< 0.0001; \**p* \< 0.0001 B~2~ versus control, 3-NPA, B~2~ + 3-NPA, B~6~, B~6~ + 3-NPA. Cerebellum/medulla oblongata: Anova F = 5.21; *p* = 0.002; \**p* \< 0.05 B2 versus control, 3-NPA, B~2~ + 3-NPA, B~6~ Fig. 4Ca^2+^, Mg^2+^ATPase activity in brain of rats treated with NaCl (G1), 3-Nitropropionic acid 3-NPA (G2), Riboflavin B~2~ (G3), Riboflavin B~2~ + 3-NPA (G4), Pyridoxine B~6~ (G5) and Pyridoxine B~6~ + 3-NPA (G6). Data presented as Mean ± SD values of percentage with respect to NaCl control group. Assays were made by triplicate. Cortex: Anova F = 36.8; *p* \< 0.0001; \**p* \< 0.001 3-NPA versus control, B~2~, B~2~ + 3-NPA, B~6~, B~6~ + 3-NPA. Striatum: Anova F = 65.01; *p* \< 0.0001; \**p* \< 0.0001 3-NPA versus control, B~2~, B~2~ + 3-NPA, B~6~, B~6~ + 3-NPA. Cerebellum/medulla oblongata: Anova F = 134.3; *p* \< 0.0001; \**p* \< 0.0001 3-NPA versus control, B~2~, B~2~ + 3-NPA, B~6~, B~6~ + 3-NPA Fig. 5H~2~O~2~ levels in brain of rats treated with NaCl (G1), 3-Nitropropionic acid 3-NPA (G2), Riboflavin B~2~ (G3), Riboflavin B~2~ + 3-NPA (G4), Pyridoxine B~6~ (G5) and Pyridoxine B~6~ + 3-NPA (G6). Data presented as Mean ± SD values of percentage with respect to NaCl control group. Assays were made by triplicate. Cortex: Anova F = 2.15; *p* = 0.08. Striatum: Kruskal--Wallis X^2^ = 4.4; *p* = 0.4. Cerebellum/medulla oblongata: Anova F = 19.9; *p* \< 0.0001; \**p* \< 0.0001 3-NPA versus control, B~2~, B~2~ + 3-NPA, B~6~, B~6~ + 3-NPA. \*\**p* = 0.03 B~2~ versus B~2~ + 3-NPA

In striatum similar results as those observed in cortex were found. 3-NPA decreased 5-HIAA concentration (Fig. [1](#Fig1){ref-type="fig"}). Rivoflavin administration produced an increase in lipid peroxidation and 3-NPA treated animals showed significant increase in ATPase activity (Fig. [4](#Fig4){ref-type="fig"}).

In the cerebellum/Medulla oblongata of the animals that received 3-NPA alone, Dopamine, H~2~O~2~ and ATPase activity increased while 5-HIAA levels were found to. In this region significant lipid peroxidation increment was observed in Rivoflavin treated group when compared with the rest of the treated animals decrease (Figs. [1](#Fig1){ref-type="fig"}, [4](#Fig4){ref-type="fig"}, [5](#Fig5){ref-type="fig"}, [6](#Fig6){ref-type="fig"}).Fig. 6Dopamine levels in brain of rats treated with NaCl (G1), 3-Nitropropionic acid 3-NPA (G2), Riboflavin B~2~ (G3), Riboflavin B~2~ + 3-NPA (G4), Pyridoxine B~6~ (G5) and Pyridoxine B~6~ + 3-NPA (G6). Data presented as Mean ± SD values of percentage with respect to NaCl control group. Assays were made by triplicate. Cortex: Anova F = 41.3; *p* \< 0.0001; \**p* \< 0.0001 3-NPA versus control, B~2~, B~2~ + 3-NPA, B~6~, B~6~ + 3-NPA. Striatum: Kruskal--Wallis X^2^ = 11.6; *p* = 0.04 (No comparisons were made due 3-NPA data dispersion). Cerebellum/medulla oblongata: Anova F = 18.1; *p* \< 0.0001 3-NPA versus control, B~2~, B~2~ + 3-NPA, B~6~, B~6~ + 3-NPA

Discussion {#Sec12}
==========

Evidence has shown that Huntington's disease (HD) can be caused by mitochondrial toxin produced as a result of striatal damaged that is provoked when the transmitter dopamine is metabolized by monoamine oxidase enzymes \[[@CR4]\]. Also, HD is a destructive neurodegenerative disorder and indicates dysfunction in the neurons that may eventually lead to death of selected brain regions; especially, the striatum and cerebral cortex \[[@CR5]\]. In recent studies, the dendritic spine density of striatal projection neurons was reported to be seriously decreased after 3-nitropropionic acid treatment \[[@CR23]\]. This finding is in conformity with the results of the present study where dopamine levels increased in cortex, striatum and cerebellum/medulla oblongata regions of animals that received 3-nitropropionic acid treatment. Moreover, it is possible that the increase in dopamine turnover produces an increase in oxygen radical by monoamine oxidase activity.

H~2~O~2~ concentration increased in cerebellum/medulla oblongata regions in animals treated with 3-NPA. This demonstrates that reactive oxygen species is the primary event in 3-NPA toxicity. In the same brain regions, lipid peroxidation increased in animals treated with riboflavin. Such increase may be due to the association of this substance with increased mitochondrial energy metabolism that is probably responsible for the high rate of oxidative metabolic activity in the brain which gives rise to intense production of reactive oxygen metabolite and subsequently to the generation of free radicals implicated in the pathogenesis of neurological disorders. These results may have relation with the reports of Kumar et al. \[[@CR24]\] and Kaur et al. \[[@CR25]\], which suggest that 3-NPA depleted GSH in cortex, although the present study was made with young animal models.

Calcium and magnesium-dependent ATPase activity increased in cortex, striatum and cerebellum/medulla oblongata regions of the animals that received 3-NPA alone. This could be attributed to changes in the affinity of the enzyme \[[@CR26]\]. These results may have relation with the reports of Naziroğlu et al. \[[@CR27]\], which suggest that increase in Ca^2+^-ATPase activities may have protective effects against substances that induce brain injury by inhibiting free radical production, regulating calcium-dependent processes and supporting the antioxidant redox system.

Conclusion {#Sec13}
==========

The results of the present study suggest that the partial increase in antioxidant capacity in brain due to B~2~ and B~6~ vitamins promotes an effect in dopamine or serotonin metabolisms when we consider 3-NPA capacity to generate oxidative stress.

We recommend that further studies be carried out to investigate the possible relationship between B~2~ and B~6~ vitamins on dopamine and serotonin levels in different animal models. Undoubtedly, we believe that this would help in the study of neurodegenerative diseases.
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